ZURICH (Reuters) - Aimmune Therapeutics Inc (O:AIMT) shareholders have backed Nestle's (S:NESN) $2 billion offer to gain full ownership of the first U.S.-approved peanut allergy treatment, which has struggled with a slow launch due to the COVID-19 pandemic.
Including shares it already held, Nestle controlled around 84% of the outstanding shares as of the $34.50 per share offer's expiration date. "The minimum tender condition to the consummation of the offer set forth in the offer to purchase has been satisfied," Nestle said.
